Use and abuse of placebo in phase III trials

European Journal of Clinical Pharmacology

Volumn 54, Issue 2, 1998, Pages 101-105

  Garcia Alonso F ^b   Guallar, E ^b   Bakke, O M ^b   Carne X ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; CISPLATIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOCLOPRAMIDE; ONDANSETRON; PLACEBO;

CLINICAL RESEARCH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEPRESSION; DRUG COMPARISON; DRUG DEVELOPMENT; ETHICS; HUMAN; METHODOLOGY; PRIORITY JOURNAL; SHORT SURVEY; VOMITING;

BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL APPROACH/SOURCE; CONTROL GROUPS; THERAPEUTIC RESEARCH;

CLINICAL TRIALS, PHASE III; CONTROL GROUPS; HUMANS; PLACEBO EFFECT; PLACEBOS; PRACTICE GUIDELINES; THERAPEUTIC HUMAN EXPERIMENTATION; WITHHOLDING TREATMENT;

EID: 0031948752     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050429     Document Type: Short Survey

References (32)

1. Lachaux B, Lemoine P (1988) Placebo: un medicament qui cherche la verité. Medsi/McGraw-Hill, Auckland/New York
2. Nies AS, Spielberg SP (1995) Principles of therapeutics. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (ed) Goodman and Oilman's The pharmacological basis of therapeutics, 9th edn. McGraw-Hill, New York pp 43-62
3. Friedman LM, Furberg CD, DeMets DL (1996) Fundamentals of clinical trials, 3rd edn. Mosby-Year Book, Saint Louis
4. Bakke OM, Carné X, Garcia-Alonso F (1994) Ensayos clínicos con medicamentos. Mosby/Doyma Libros, Barcelona
5. Collier J (1995) Confusion over use of placebos in clinical trials. BMJ 311: 821-822
6. Temple R (1997) Choice of control group in clinical trials. European Agency for the Evaluation of Medicinal Products, London, CPMP/ICH/364/96
7. Hrobjartsson A (1996) The uncontrollable placebo effect. Eur J Clin Pharmacol 50: 345-348
8. Rothman KJ, Michels KB (1994) The continuing unethical use of placebo controls. N Engl J Med 331: 394-398
9. Aspinall RL, Goodman NW (1995) Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. BMJ 311: 844 846
10. Rothman KJ (1996) Placebo mania. BMJ 313: 3-4
11. Parsons HM (1974) What happened at Hawthorne? Science 183: 922 932
12. Guallar E, Jiménez FJ, García-Alonso F, Bakke OM (1997) La regresión a la media en la investigatión y práctica clinica. Med Clin (Barc) 109: 23 26
13. Beck TM, Ciociola AA, Jones SE, Harvey WH. Tchekmedyian NS, Chang A, et al (1993) Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group. Ann Intern Med 118: 407-413
14. Citron ML (1993) Placebos and principles: a trial of ondansetron. Ann Intern Med 118: 470-471
15. Rust M, Cohen LA (1994) Single oral dose ondansetron in the prevention of postoperative nausea and emesis. The European and US Study Groups. Anaesthesia [Suppl] 49: 16-23
16. Laporte JR, Figueras A (1994) Placebo effects in psychiatry. Lancet 344: 1206-1209
17. MacDonald TM, McMahon AD, Reid IC, Fenton GW, McDevitt DG (1996) Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ 313: 860-861
18. th edn. Merck, Rahway New Jersey
19. Starr I, Luchi RJ (1969) Blind study on the action of digitoxin on elderly women. Am Heart J 78: 740-751
20. Braunwald E (1991) ACE inhibitors-a cornerstone of the treatment of heart failure. N Engl J Med 325: 351-353
21. Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, et al (1993) Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. J Am Coll Cardiol 22: 65-72
22. Cowley AJ, Wynne RD, Swami A, Birkhead J, Skene A, Hampton JR (1992) A comparison of the effects of captopril and flosequinan in patients with severe heart failure. Cardiovasc Drugs Ther 6: 465-470
23. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406-412
24. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias Manno D, Barker AH, et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324: 781-788
25. The Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327: 227-233
26. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348: 7-12
27. Angell M (1997) The ethics of clinical research in the Third World. N Engl J Med 337: 847-849
28. Lurie P, Wolfe SM (1997) Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med 337: 853-856
29. Anonymous (1997) The ethics industry. Lancet 350: 897
30. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al (1994) Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331: 1173-1180
31. Varmus H, Satcher D (1997) Ethical complexities of conducting research in developing countries. N Engl J Med 337: 1003 1005
32. Aaby P, Babiker A, Darbyshire J, Nunn A, Barreto S, Alonso P, et al (1997) Ethics of HIV trials. Lancet 350: 1546